| Literature DB >> 31672916 |
Jon M Steichen1,2,3, Ying-Cing Lin4, Colin Havenar-Daughton3,5, Simone Pecetta4, Gabriel Ozorowski2,3,6, Jordan R Willis1,2,3, Laura Toy3,5, Devin Sok1,2,3, Alessia Liguori1,2,3, Sven Kratochvil4, Jonathan L Torres2,3,6, Oleksandr Kalyuzhniy1,2,3, Eleonora Melzi4, Daniel W Kulp1,2,3,7, Sebastian Raemisch1,2,3, Xiaozhen Hu1,2,3, Steffen M Bernard2,3,6, Erik Georgeson1,2,3, Nicole Phelps1,2,3, Yumiko Adachi1,2,3, Michael Kubitz1,2,3, Elise Landais1,2,3, Jeffrey Umotoy1,2,3, Amanda Robinson1,2,3, Bryan Briney1,2,3,8, Ian A Wilson2,3,6,9, Dennis R Burton1,2,3, Andrew B Ward2,3,6, Shane Crotty10,5,11, Facundo D Batista12,13, William R Schief14,2,3,4.
Abstract
Vaccine induction of broadly neutralizing antibodies (bnAbs) to HIV remains a major challenge. Germline-targeting immunogens hold promise for initiating the induction of certain bnAb classes; yet for most bnAbs, a strong dependence on antibody heavy chain complementarity-determining region 3 (HCDR3) is a major barrier. Exploiting ultradeep human antibody sequencing data, we identified a diverse set of potential antibody precursors for a bnAb with dominant HCDR3 contacts. We then developed HIV envelope trimer-based immunogens that primed responses from rare bnAb-precursor B cells in a mouse model and bound a range of potential bnAb-precursor human naïve B cells in ex vivo screens. Our repertoire-guided germline-targeting approach provides a framework for priming the induction of many HIV bnAbs and could be applied to most HCDR3-dominant antibodies from other pathogens.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31672916 PMCID: PMC7092357 DOI: 10.1126/science.aax4380
Source DB: PubMed Journal: Science ISSN: 0036-8075 Impact factor: 47.728